Answer
Modified-release tablets are licensed for stones associated with low urinary citrate or chronic calcium oxalate stones, recurrent uric acid stones, cystine stones and calcium stones associated with renal tubular acidosis.
Sources for this answer
- Renodyra 1080 mg modified-release tabletsemc · SmPC Current selected SmPC · Version 1